Identification of peculiar gene expression profile in peripheral blood mononuclear cells (PBMC) of celiac patients on gluten free diet. by Sangineto, Moris et al.
RESEARCH ARTICLE
Identification of peculiar gene expression
profile in peripheral blood mononuclear cells
(PBMC) of celiac patients on gluten free diet
Moris Sangineto1, Giusi Graziano2, Simona D’Amore1¤a, Roberto Salvia1,
Giuseppe Palasciano3, Carlo Sabbà1, Michele Vacca1¤b, Marica Cariello1,4*
1 Department of Interdisciplinary Medicine, “Aldo Moro” University of Bari, Bari, Italy, 2 National Cancer
Research Center, IRCCS Oncologico Giovanni Paolo II, Bari, Italy, 3 Department of Biomedical Sciences and
Human Oncology, Clinica Medica “A. Murri”, “Aldo Moro” University of Bari, Bari, Italy, 4 INBB, National
Institute for Biostructures and Biosystems, Rome, Italy
¤a Current address: Department of Medicine, University of Cambridge, Cambridge, United Kingdom
¤b Current address: Department of Biochemistry and Institute of Metabolic Science, University of Cambridge,
Cambridge, United Kingdom
* maricacariello@gmail.com
Abstract
Celiac disease (CD) is a systemic disorder characterized by an immune-mediated reaction
to gluten and a wide spectrum of clinical manifestations. Currently, the main treatment of
CD is represented by adherence to a gluten-free diet (GFD) which determines the resolution
of symptoms, and the normalization of the serology and of the duodenal villous atrophy. In
the present study, we aimed to identify changes in gene expression in peripheral blood
mononuclear cells (PBMCs) of celiac patients on GFD for at least 2 years, in order to identify
novel disease biomarkers and candidate targets for putative therapeutic approaches. Micro-
array analysis was performed on PBMCs from 17 celiac patients on long-term GFD and 20
healthy controls. We identified 517 annotated genes that were significantly modulated
between celiac patients and controls. Significant biological pathways were functionally clus-
tered using the Core Function of Ingenuity System Pathway Analysis (IPA). Intriguingly,
despite being on a GFD, celiac patients exhibited a peculiar PBMC profile characterized by
an aberrant expression of genes involved in the regulation of immunity, inflammatory
response, metabolism, and cell proliferation. Random forest algorithm was then used to vali-
date the prediction ability of core genes as classifiers of the “celiac status”. In conclusion,
our study identified a characteristic PBMCs signature profile in clinically asymptomatic
celiac patient.
Introduction
Celiac disease (CD) is an inflammatory, systemic disease characterized by an immune-medi-
ated response triggered by dietary gluten exposition that leads to a variable damage of small-
intestinal mucosa, a specific serum autoantibody response and a wide spectrum of clinical
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manifestations [1]. CD is one of the most common disease occurring in with 1% of the popula-
tion worldwide, and predominantly affects infants and young children, although it may
develop at any age in genetically susceptible individuals [2]. A combination of genetic predis-
position, environmental factors (i.e. gluten diet) and cofactors (e.g. microbiota alterations,
viral infections, drugs, wining age) determines the etiology of this disease [3]. The genetic pre-
disposition is determined by HLA-DQ2 haplotype (DQA10501/DQB10201), which is
expressed in 90% of celiac population, while 5% is represented by HLA-DQ8 haplotype
(DQA10301/DQB10302) [1]. HLA class II genotype expressed on the cell surface of antigen-
presenting cells plays an essential role in CD by presenting gliadin peptides to CD4+ Th1 cells,
which trigger an immune response leading to the production of inflammatory cytokines, such
as IFN- [4]. Nevertheless, despite CD is strongly associated with specific HLA class II genes,
other factors may be important in the promoting disease onset also given that 30% of the gen-
eral population expresses HLA DQ2; and other 39 celiac disease risk loci have been discovered
[5]. During the pathogenesis of celiac disease an inflammatory cascade occurs, involving Th1
activation and an innate immune response in the intestinal mucosa, characterized by cytokines
production such as interleukin 15 (IL-15), which promotes the differentiation of intraepithelial
lymphocytes into cytotoxic CD8+ T cells [4]. A key role in lymphocyte proliferation/activation
and enterocyte alteration is also played by nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-kB) pathways activation [6]. As a result of this pro-inflammatory cascade is
the damage thus leading to villus atrophy and crypt hyperplasia. The main treatment for CD is
the gluten free diet (GFD). Adherence to GFD for 6–26 months is able to promote the resolu-
tion of symptoms, the normalization of serology markers and duodenal villous atrophy [7].
Nevertheless, despite treatment, patients with CD are at higher risk of death for cardiovascular
disease and cancer, as shown by Ludvigsson et al. in a wide retrospective Swedish cohort [8].
CD patients following GFD recommendation exhibit T lymphocytes specific to deamidated
gluten peptides in the peripheral blood, which are able to produce pro-inflammatory cytokines
such as IFN-gamma and IL-6 [9]. Therefore, a low grade undetectable pro-inflammatory status
might be still present in GD patients despite GFD and might pathophysiologically explain the
epidemiological association with CVR. In the present study we compared the whole genome
expression profile of peripheral blood mononuclear cells (PBMCs) of celiac patients on GFD
for at least 2 years to those of healthy subjects, in order to identify changes in the transcriptome
that characterizes the celiac patients on GFD. PBMCs, the circulating immune cells mainly
constituted by T lymphocytes (70%), B lymphocytes (15%), natural killer cells (10%),
monocytes (5%), and dendritic cells (1%), [10]. play a key role in the inflammatory system,
and the changes in their gene expression are considered predictors of the whole body inflam-
matory status in different conditions [10]. In the present study, we identified different gene
expression profiles in PBMCs which could represent hallmarks of CD independent from GFD.
Materials and methods
Study population
Patients recruitment and clinical and biochemical assessment were collected at the Clinica
Medica “A. Murri” (University Hospital of Bari, Italy). Seventeen celiac patients and twenty
healthy subjects were recruited. The diagnosis of celiac disease was carried out at least two
years before the study through measurement of antibodies and biopsy of duodenum, whose
histology was evaluated by a pathologist and expressed according to Marsh-Oberhuber classifi-
cation (Table 1). After 12 months of GFD, antibodies measurement and duodenal biopsy were
performed, showing antibody negativity and normalization of the duodenal mucosa. During
the study recruitment the patients were on GFD since at least two years (Table 1) and were
Gene expression profile in celiac patients on gluten free diet
PLOS ONE | https://doi.org/10.1371/journal.pone.0197915 May 24, 2018 2 / 17
newly submitted to antibodies assessment in order to exclude any positivity. The controls
underwent the same biochemical analysis and they have never been biopsied. Baseline charac-
teristics of subjects are described in Table 2. The presence of viral hepatitis, HIV infection, and
daily alcohol consumption over 25 g/day were part of the exclusion criteria. In all subjects the
past medical history and anthropometric parameters (weight, height and body mass index)
were collected. All subjects underwent the physical examination. Blood samples were used for
biochemical examinations, including the measurement of anti-transglutaminase antibodies (t-
TG IgA and t-TG IgG), and anti-endomysium antibodies (EMA). Other peripheral blood sam-
ples were used for HLA II haplotype study and for PBMCs isolation. The study protocol was
approved by the Ethical Committee of the Azienda Ospedaliero-Universitaria Policlinico di
Bari, Italy. All patients gave their written informed consent for the use of clinical data and
blood samples for scientific research purposes connected to this study.
Biochemical measurements
After overnight fasting, serum was collected for the evaluation of standard biochemical mark-
ers of glucose and lipid metabolism, liver and renal function, complete blood count, iron status
and inflammation by standard biochemical methods using a standard, previously validated
protocol [11]. Moreover, t-TG IgA and t-TG IgG were measured by enzyme-linked immuno-
sorbent assay (automated analyser, Dynex Technologies, Chantilly, VA USA), while EMA pos-
itivity was assessed by indirect immunofluorescence.
Sample collection and PBMC isolation
Fresh whole blood (18 ml) was collected by standardized venepuncture in EDTA anti-coagu-
lant tubes (Vacuette1, Greiner Bio-One, Kremsmunster, Austria). PBMCs were isolated at
once, after collection of blood samples, using standard and previously validated protocol
[11;12]. PBMC were isolated by density separation over a Ficoll-Paque (GE healthcare, Swe-
den) gradient.
RNA extraction and reverse-transcription
Total RNA was extracted from the PBMCs pellet by QIAzol1 Lysis Reagent (Qiagen, Hilden,
Germany), according to the manufacturer’s instructions using standard and previously vali-
dated protocol [11]. To avoid possible DNA contamination, the RNA was treated with DNA-
ase-1 (Ambion, Foster City, CA). RNA purity (A260/A280 > 1.75), and the concentration was
checked by spectrophotometer, while the RNA integrity was assessed by Bio-RAd ExperionTM
Table 1. Characteristics of celiac patients.
Age (years) 35.3 ± 11.3
Gender 29.4% M (n5); 70.6% F (n12)
Time on GFD (years) 5.8 ± 3.8
HLA II haplotype 70.6% DQ2 (n12); 29.4% DQ8 (n5)
Marsh-Oberhuber grading 23.5% type 2 (n4); 11.8% type 3a (n2); 23.5% type 3b (n4); 41.2% type 3c (n7)
t-TG IgA (AU/mL) 100 ± 67.4
t-TG IgG (AU/mL) 12.5 ± 25
EMA 82.4% positive (n14); 17.6% negative (n3)
GFD: gluten free diet; HLA: Human leukocyte antigen; t-TG IgA: anti-transglutaminase IgA antibodies (cutoff: 10
AU/mL); t-TG IgG: anti-transglutaminase IgG antibodies (cutoff: 10 AU/mL); EMA: anti-endomysium antibodies.
https://doi.org/10.1371/journal.pone.0197915.t001
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Table 2. Clinical characterization of the study population.
Clinical variable Control Celiac p-value
n 20 17 -
Weight (Kg) 68.03±10.45 59.97±10.27 NS
BMI (Kg/m2) 23.27±2.11 21.34±4.18 NS
Height (m) 1.71±0.08 1.66±0.06 NS
Glucose (mg/dl) 87.60±7.36 87.35±11.73 NS
Total cholesterol (mg/dl) 180.05±29.07 162.94±33.62 <0.05
HDL-c (mg/dl) 58.65±11.58 52.53±13.60 NS
LDL-c (mg/dl) 106.45±26.72 94.18±24.06 NS
TG (mg/dl) 69.70±32.47 71.94±36.35 NS
AST (U/I) 22.40±14.04 25.88±16.21 NS
ALT (U/I) 35.65±24.86 49.00±32.57 <0.05
GGT (U/I) 26.60±20.18 30.41±28.49 NS
ALP (U/I) 65.20±23.90 86.29±32.73 <0.05
Total bilirubin (mg/dl) 0.52±0.19 0.62±0.56 NS
Direct bilirubin (mg/dl) 0.13±0.08 0.13±0.07 NS
Indirect bilirubin (mg/dl) 0.39±0.17 0.49±0.49 NS
Creatinine (mg/dl) 0.81±0.16 0.73±0.18 NS
BUN (mg/dl) 3.56±0.67 4.17±1.03 NS
Uric acid (mg/dl) 33.65±7.65 29.00±6.23 NS
Total protein (g/dl) 7.27±0.39 7.39±0.60 NS
Albumin (g/dl) 4.22±0.26 4.08±0.27 NS
Sodium (mEq/l) 138.20±2.04 139.65±2.87 NS
Potassium (mEq/l) 3.93±0.35 4.19±0.34 <0.05
Magnesium (mg/dl) 1.84±0.20 1.99±0.15 <0.05
Calcium (mg/dl) 8.87±0.41 9.01±0.43 NS
ESR (mm/h) 5.60±4.39 8.29±5.60 NS
CRP (mg/l) 0.20±0.00 0.24±0.18 NS
Iron (ug/dl) 94.82±31.21 78.41±32.00 NS
Transferrin (mg/dl) 239.91±50.70 262.41±59.35 NS
Ferritin (ng/ml) 96.11±79.86 94.83±153.14 NS
PT INR 1.05±0.09 1.02±0.05 NS
LDH (U/L) 131.05±29.46 162.41±53.02 <0.01
TSH (mUI/L) 1.86±0.53 1.93±0.94 NS
FT3 (pg/ml) 2.99±0.23 3.05±0.45 NS
FT4 (ng/dl) 1.07±0.13 1.08±0.18 NS
Thyroglobulin (ng/ml) 13.73±9.88 7.16±4.73 <0.05
Ab anti TG (UI/ml) 3.10±6.56 46.77±72.55 NS
Ab anti TPO (UI/ml) 2.13±1.32 51.55±101.18 <0.01
HLA-DQ8 negative positive (30%) -
HLA-DQ2 negative Positive (70%) -
25-OH-D (ng/ml) 32.04±4.52 28.76±12.31 NS
Hemoglobin (g/dl) 13.87±1.15 12.91±1.54 NS
MCV (fl) 83.48±2.60 83.41±7.09 NS
WBC (103/μl) 6.28±1.32 5.97±1.52 NS
Monocytes (%) 6.39±1.55 6.54±2.11 NS
Lymphocytes (%) 35.25±8.71 36.41±6.64 NS
Neutrophils (%) 54.31±8.98 54.15±7.07 NS
(Continued)
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(Bio-Rad, Hercules, CA). Only the samples with Relative Quality Index (RQI) > 8 were used
for reverse-transcription. According to the manufacturer’s instructions, cDNA was synthe-
sized by reverse-transcribing 4 μg of total RNA in a volume of 100 μl using the High Capacity
DNA Archive Kit (Applied Biosystems, Foster Cyti, CA). For TaqMan gene validations, due to
the small quantity of RNA achieved, we used a High Capacity RNA-to-cDNA Kit (Applied
Biosystems, Foster City, CA) to reverse-transcribe 10 ng of total RNA in a volume of 20 μl.
Microarray analysis for gene expression profiling
We conducted microarray gene expression analysis on total RNA (400 ng) extracted from
PBMCs. amplified using the Illumina Total Prep RNA Amplification kit (Ambion, Austin, TX,
US) following the manufacturer’s instructions. For the whole-genome expression we used the
Illumina whole genome direct hybridization assay (Illumina HumanHT-12-V3’ Expression
Kit) on the Illumina microarray platform (Illumina iScan System) using standard and previ-
ously validated protocol [13]. Data were processed using the Illumina Genome Studio Software
through specific algorithms of filtration and cleaning of the signal [13]. Data were normalized
with the quantile method. Final output consisted of normalized fluorescence intensity of each
probe (AVG signal), representing the expression levels of each gene. Genes with AVG signal
lower/equal to the background or with detection p value.0.001 was excluded. We also excluded
genes discontinued or poorly annotated according to NCBI Entrez Gene Database records.
We thus performed pathways analysis on a final number of 517 significant genes (Fold.1.5;
p<0.05) using the ‘‘Core Analysis” function of Ingenuity Pathway Analysis (Ingenuity System
Inc., USA) to identify networks and pathways modulated in GFD celiac patients vs healthy
controls. Microarray data are available on GEO (Ref: GSE113469; https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE113469).
Quantitative real-time polymerase chain reaction (RTqPCR)
PCR assays were performed in 96 well optical reaction plates using the ABI 7500HT system
(Applied Biosystems, Foster City, CA) using standard and previously validated protocol [11].
PCR assays were conducted in triplicates for each sample. To validate our microarrays results,
we used TaqMan1 Gene Expression Assays and TaqMan1 Universal PCR Master Mix with
UNG following the manufacturer’s instructions. The following PCR conditions were used:
UNG incubation at 50˚C for 2 min (only for TaqMan); then (for all the experiments) denatur-
ation at 95˚C for 10 min, followed by 40 cycles at 95˚C for 15 s, and then at 60˚C for 60 s. Base-
line values of amplification plots were set automatically, and threshold values were kept
Table 2. (Continued)
Clinical variable Control Celiac p-value
Basophils (%) 0.51±0.24 0.41±0.18 NS
Eosinophils (%) 3.44±1.54 2.35±1.72 <0.01
BMI: body mass index; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; TG:
triglycerides; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: -glutamyltranspeptidase; ALP:
alkaline phosphatase; BUN: blood urea nitrogen; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein;
PT-INR pro-thrombin international normalised ratio; LDH: lactate dehydrogenase; TSH: thyroid stimulating
hormone; FT3: free triiodothyronine; FT4: free thyroxine; Ab anti TG: anti thyroglobulin antibodies; Ab anti TPO:
anti thyroperoxidase antibodies; MCV: mean corpuscular volume; WBC: white blood cells.
https://doi.org/10.1371/journal.pone.0197915.t002
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constant to obtain normalized cycle times and linear regression data. Relative quantification
was performed using the ΔΔCT method. Values were plotted as fold change ± SEM.
Statistical analysis
In order to evaluate differences between the two groups of interest the normalized data
exported from genome studio software were analyzed with Mann-Whitney U test while a cor-
relation between continuous variables were assessed using the Pearson’s correlation coeffi-
cient. p-values < 0.05 were considered statistically significant. A fold induction of ±1.5 was
considered the minimum acceptable cut-off and the raw p-values were adjusted by the Benja-
mini-Hochberg procedure to control the False Discovery Rate (FDR) [14;15]. We considered
“biologically relevant” (15) only genes statistically significant and highlighted by pathway anal-
ysis. To study the ability of this set of genes to characterize celiac patients from controls and to
mitigate the impact of small sample size on the study conclusions the more robust and innova-
tive Random Forest Analysis was applied. A Random Forest (RF) is a classification algorithm
consisting of an ensemble technique that overcomes the problem of a low number of observa-
tions [16;17]. The principal characteristics of RF are the identification and classification of rel-
evant differentially expressed genes [16] and the estimation of the error rate related to their
predictive ability. This efficient approach, considering that a RF with a low error rate (high
C-Index) is a strong classifier, gave us the possibility to define an “identity card” of the genes
characterizing celiac patients.
The ROC curve analysis was applied to the selected genes (5 up-regulated, 5 down-regu-
lated) in order to estimate their ability to discriminate celiac patients from healthy controls.
The area under the ROC curve (AUC) was used as a measure of the capability of each gene to
distinguish between the two clinical groups.
All the analyses were performed using the SAS Package (Release 9.1) and the R Package
(Version 2.12.2).
Results
Clinical characterization of the study population
Seventeen celiac patients on GFD for at least 2 years were compared to twenty healthy controls.
We show the baseline characteristics of the study population in Table 2. Susceptibility to celiac
disease is linked to the presence of HLA-DQ2 and HLA-DQ8 heterodimers. Accordingly, 70%
of the celiac patients in our population presented HLA-DQ2 heterodimer and 30% HLA-DQ8
heterodimer, while these genetic markers were completely absent in healthy subjects. Celiac
disease is a systemic disease characterized by a specific serum autoantibody profile and a wide
spectrum of clinical manifestations. Celiac population on GFD exhibited a normal serum auto-
antibody profile (Table 1). Although within normal values, alkaline phosphatase (ALP), ala-
nine aminotransferase (ALT), potassium, magnesium, lactate dehydrogenase (LDH) and anti
thyroperoxidase antibodies (Ab anti-TPO) levels resulted increased while total cholesterol,
thyroglobulin and eosinophils were significantly lower in celiac patients compared to controls.
Whole genome analysis in PBMCs of celiac patients on GFD
We used whole-genome microarray analysis to analyze global changes to the transcriptome in
PBMCs from celiac patients on GFD. Overall, the signal intensity of 4482 genes resulted statis-
tically different by the Mann-Whitney U test in celiac (vs. control), thus underscoring a pro-
found diversity in the activation status of the PBMCs of celiac patients on GFD when
compared to healthy controls. In order to evaluate the peculiarities of celiac patients vs
Gene expression profile in celiac patients on gluten free diet
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controls, we selected 517 annotated genes (261 up-regulated and 256 down-regulated) that
were significantly different in celiac population compared to healthy subjects (P<0.01;
FDR<0.01). To provide an interpretation of our results, significant biological pathways were
functionally clustered using the Core Function of Ingenuity System Pathway Analysis (IPA).
We considered ‘biologically relevant’ only those ‘statistically significant’ genes included in ‘sig-
nificantly modulated’ pathways and networks (Figs 1A and 2A). The profiling of CD patients
revealed a “pro-inflammatory” shift as shown confirmed by the dysregulation of pathways
involved in the control of the immune system and inflammatory response. The Random Forest
(RF) algorithm was used to validate the prediction ability of “celiac status” of the selected gene
set The accuracy of core genes in classifying CD patients was estimated by the algorithm as
high as 100% (C-Index 1; Figs 1B and 2B) thus suggesting that CD PBMCs have a specific tran-
scriptome signature when compared to healthy controls.
“Identity card” of celiac patients on gluten free diet for at least 2 years
In order to evaluate the biological meaning of the changes in GE of PBMCs in CD, we analyzed
the genes differentially expressed among the groups using IPA pathways, network and
“upstream regulator” prediction tools (Figs 1A and 2A). By using a validated quantitative real-
time PCR method, we assessed the mRNA expression of 11 genes (5 up-regulated and 6 down-
regulated) involved in the modulation of immunity system, cell proliferation and metabolism.
We observed a significant increase in the mRNA levels of mitogen-activated protein kinase 1
(MAPK1), heat shock protein 70 (HSPA1a), toll-like receptor 5 (TLR-5) and tumor necrosis fac-
tor superfamily member 10 (TNFSF10) involved in both innate and adaptive immune responses
(Fig 3A). Moreover, we also confirmed the up-regulation of nuclear factor erythroid-derived 2
(NFE-2), an essential factor in the maturation of platelets and red cells (Fig 3A). In line with
these results, we validated the down-regulation of chemokine (C-C Motif) ligand 2 (CCL2),
CD83, triggering receptor expressed on myeloid cells (TREM1) and interleukin 1b (IL-1b) in
celiac patients compared to control group (Fig 3B). The involvement of these molecular patterns
points to an intriguing activation of innate immune pathways in celiac patients despite long-
term GFD. Finally, we observed a downregulation of ATP-binding cassette A1 (ABCA1), a gene
that promotes cholesterol efflux leading to HDL formation, and NR4A2 (NURR1), a nuclear
receptor involved in inflammation in microglia and astrocytes (Fig 3B).
In order to prove the ability of the up-regulated and down-regulated gene sets to discrimi-
nate the “celiac status”, we calculated the ROC curves (Figs 4A and 5A). Up- and down-regu-
lated genes were characterized by high specificity and sensibility in predicting the “celiac
status”. Particularly, HSPA1a and CCL2 cut-off values were able to classify celiac status with
high accuracy (Figs 4B and 5B) confirming a specific gene expression “identity card” of GFD
celiac patients.
Discussion
Celiac disease is a gluten-sensitive autoimmune disease affecting genetically susceptible indi-
viduals, which results in small-intestinal mucosal injury leading to malabsorption and
Fig 1. Gene expression profiling in GFD celiac patients. (A) Genes up-regulated in GFD celiac patients were profiled using microarrays, and
clustered in large networks displaying a coordinate biological function. Data are shown in a heatmap with a matrix format of the genes differentially
modulated within the specific network; single rows represent gene expression in a single patient (column). Colours: red, expression greater than the
mean; black, expression equal to the mean; green, expression smaller than the mean. Lateral bars: fold changes among groups. (B) Proximity matrix of
the RF algorithm: RF discriminated patients with celiac disease on GFD from control patients in 100% of cases (C-Index = 1). Legend: (black)
controls; (white) celiac patients.
https://doi.org/10.1371/journal.pone.0197915.g001
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malnutrition-related problems, including chronic diarrhea, bloating, weight loss, anemia, iron
deficiency, headache, chronic fatigue, and osteoporosis [18]. Genetic predisposition
(HLA-DQ2 and HLA-DQ8 haplotypes), with positive duodenal biopsy and serological anti-
bodies upon gluten contained diet are required for the diagnosis of CD [18;19]. In most cases
the gluten free diet alone is able to restore villous atrophy and normalize serology markers in
celiac patients, who are thus considered “healthy subjects”, although some authors reported
that the mortality risk among patients with CD or latent CD is modestly increased [8;20].
In the present work, we compared the PBMCs transcriptome of celiac patients on long
term GFD, characterized by negative antibodies and normal duodenal mucosa, with healthy
subjects in order to identify a specific gene expression pattern of CD. The clinical parameters
of the population were analyzed and, as expected, we found significant differences between
celiac group and controls. In particular, we observed raised anti thyroperoxidase and thyro-
globulin antibodies (Table 2) in the celiac group thus confirming the well-known association
Fig 2. Gene expression profiling in GFD celiac patients. (A) Genes down-regulated in GFD celiac patients were profiled using microarrays, and clustered
in large networks displaying a coordinate biological function. Data are shown in a heatmap with a matrix format of the genes differentially modulated
within the specific network; single rows represent gene expression in a single patient (column). Colours: red, expression greater than the mean; black,
expression equal to the mean; green, expression smaller than the mean. Lateral bars: fold changes among groups. (B) Proximity matrix of the RF algorithm:
RF discriminated patients with celiac disease on GFD from control patients in 100% of cases (C-Index = 1). Legend: (black) controls; (white) celiac patients.
https://doi.org/10.1371/journal.pone.0197915.g002
Fig 3. RT–qPCR confirmations: relative mRNA expression of (A) HSPA1a, TNFSF10, MAPK1, NFE2, TLR5; (B) ABCA1, CCL2, CD83,
TREM1, IL1β and NR4A2. Cyclophilin was used as reference gene, and values were normalized to data obtained from control patients.
Data were plotted as fold change ± SEM ( = p 0.05).
https://doi.org/10.1371/journal.pone.0197915.g003
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between CD and autoimmune thyroiditis [21]. Interestingly, we profiled 517 differentially
expressed genes (261 up-regulated and 256 down-regulated) in the celiac population involved
in the modulation of the immune system, the inflammatory response and metabolism, and the
pathogenesis of cardiovascular disease and cancer (Figs 1A and 2A). These genes were able to
discriminate the two populations with 100% of accuracy (Figs 1B and 2B), shedding light, for
the first time, on a peculiar transcriptome signature in PBMCs of celiac patients. A recent
study demonstrated that PBMCs of celiac patients had a systemic activation and high cytokine
expression levels, especially IFN-γ, IL-4 and IL-8 while celiac patients on GFD for 1 or 2 years
restored normal levels [22]. Therefore, we focused on biologically relevant genes and we
observed an up-regulation of HSPA1a, MAPK1, TLR-5, TNFSF10 and down-regulation of
CCL2, CD83 and IL-1β. HSPA1a gene encodes for heat shock protein (HSP) 70–1 located in
the MHC class III region. This gene is particularly interesting since the HSP70-1 seems to be
overexpressed in CACO-2 cells after gliadin exposure, mediating the cytoskeletal and tight
junction repair during recovery stage in intestinal cells [23]. It is also involved in autoim-
mune-like systemic disorder and cancer [24]. Moreover, HSP-70 overexpression in mouse
fibrosarcoma cells was demonstrated to confer resistance to killing by immune cells [25] and it
was correlated with Ki-67 positivity in lung cancer [26] as well as with increased tumor grade
and poor prognosis [27;28]. HSP-70 inhibits the intrinsic and extrinsic apoptosis pathways
blocking BAX translocation to mitochondria. A study performed on Navarra’s community
suggested that HSP-70 was a predisposing gene to develop the CD clinical symptoms as the
authors found an association between HSP-70 gene polymorphisms and celiac disease [29;30].,
With regards to inflammation, we found a drammatic up-regulation of TLRs pathway genes,
especially of TLR5, which is involved in bacterial flagellin recognition [31] and in the onset of
many diseases such as inflammatory bowel disease. Furthermore, TLRs overexpression has
been associated to celiac disease [32], and accordingly to this observation, the stimulation of
PBMCs from celiac patients with pepsin digest of wheat gliadin fraction led to IL-1β secretion
via TLR4/MyD88/TRIF/MAPK/NF-kB signaling pathway [33].
Conform to our hypothesis, we have found the upregulation of MAPK1 in GFD celiac sub-
jects. An aberrant activation of the MAP kinase pathway has been demonstrated in PBMCs of
CD patients with active disease [34], indeed MAP kinase cascade plays a regulatory role in
both innate and adaptive immune responses [35;36]. Therefore, the significant differences in
the transcriptome between the two study groups confirm the hypothesis that celiac subjects
preserve the “genetic memory” of the active disease despite GFD. This memory is expressed by
the aberrant transcription of genes involved in cellular repair and apoptosis regulation like
HSPA1a, and an important alteration of innate immunity characterized by the hyper-activa-
tion of TLRs-MAPKs axis.
On the other hand, the downregulation of genes involved in innate acute immune response
triggered by gliadin ingestion, such as CCL2, CD83 (marker of human dendritic cells), IL-1β
and TREM1 was also observed. Raised levels of chemokines like monocyte chemoattractant
protein-1 (MCP-1 also called CCL2) and pro-inflammatory mediators like IL-1β [37;38] have
been observed in the primary immune response to gluten in CD patients [39;40]. TREM-1 is
expressed mainly on the surface of granulocytes, monocytes and neutrophils [41;42] and its
induction leads to activation of a cascade of intracellular events resulting in MCP-1 and IL-1β
production. Our data suggested that whilst GFD is unable to counteract the activation of TLRs
Fig 4. Up-regulated genes in PBMCs as candidate biomarkers of celiac patients on GFD. (A) The ROC curves were characterized by specificity and
sensitivity. (B) The cut-off values obtained with the ROC curves were able to discriminate GFD celiac patients from controls. Each patient is
represented by a dot. Legend: (black) controls; (white) celiac patients.
https://doi.org/10.1371/journal.pone.0197915.g004
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pathway can normalize cytokines production and the adaptive immunity recruitment as sug-
gested by the down-regulation CCL2, IL-1β and CD83. Also, given the crucial role of TREM-1
in the regulation of innate immunity since it is a synergist of TLRs signaling cascade activated
by LPS and other ligands [42;43]. Its down-regulation might be a compensative attempt to
counteract the over-activation of TLRs seen in GFD celiac patients resulting in no cytokines
and chemokines production. However, further studies are needed to clarify this point.
In summary, this study unveiled a specific “identity card” of GFD celiac patients, which dif-
ferentiates them from healthy subjects. In fact, these patients exhibited a peculiar PBMC gene
expression profile suggesting increased cellular repair and proliferation and dysfunctional
innate immunity, which could make these subjects susceptible to autoimmune diseases and
cancer.
In order to improve the therapy strategies, further studies are necessary to understand why
celiac patients on gluten free diet exhibited a different gene expression profile in PBMCs com-
pared to control subjects. A possible explanation is that GFD celiac patients were not “strictly”
adherent to diet. In line with this, a recent study has shown that patients with celiac disease try-
ing to follow a GFD have imperfect knowledge of the gluten content of common foods which
they may encounter [44]. In this light, further research is warranted to better investigate the
nutritional habits of celiac patients (e.g. trough specific questionnaires) as well as studies
including control subjects on GFD to clarify the role of gluten on gene expression profile. Fur-
thermore, in the present study controls were HLA DQ2/DQ8 negative; whilst this allowed to
exclude any pro-inflammatory profile due to possible gluten reactivity, on the other hand rep-
resented a significant difference between the two study groups. It has been demonstrated that
the intestinal epithelial cells from subjects with only family history of CD produce more
HSP70 and IL-15 than controls, while intraepithelial cytotoxic T cells expressed higher levels
of activating NK receptors than controls, although lower when compared to active CD [45].
The genetic background of celiac patients relatives was thus sufficient to have a different
inflammatory pattern in the intestinal mucosa when compared to controls. In conclusion, in
the present study, we depicted a comparative whole genome expression chart from PBMCs in
GFD celiac patients and in healthy subjects. This strategy allowed us to identify a set of genes
characterizing GFD celiac patients as well as novel putative biomarkers of celiac status.
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